These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 10935889)
21. Impact of repeated cycles of EGF bispecific angiotoxin (eBAT) administered at a reduced interval from doxorubicin chemotherapy in dogs with splenic haemangiosarcoma. Borgatti A; Fieberg A; Winter AL; Stuebner K; Taras E; Todhunter D; Masyr A; Rendhal A; Vallera DA; Koopmeiners JS; Modiano JF Vet Comp Oncol; 2020 Dec; 18(4):664-674. PubMed ID: 32187827 [TBL] [Abstract][Full Text] [Related]
22. Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma. Finotello R; Stefanello D; Zini E; Marconato L Vet Comp Oncol; 2017 Mar; 15(1):25-35. PubMed ID: 25623994 [TBL] [Abstract][Full Text] [Related]
23. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. MacEwen EG; Kurzman ID; Helfand S; Vail D; London C; Kisseberth W; Rosenthal RC; Fox LE; Keller ET; Obradovich J J Drug Target; 1994; 2(5):391-6. PubMed ID: 7704483 [TBL] [Abstract][Full Text] [Related]
24. Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991-1993). Wood CA; Moore AS; Gliatto JM; Ablin LA; Berg RJ; Rand WM J Am Anim Hosp Assoc; 1998; 34(5):417-21. PubMed ID: 9728473 [TBL] [Abstract][Full Text] [Related]
25. VAC protocol for treatment of dogs with stage III hemangiosarcoma. Alvarez FJ; Hosoya K; Lara-Garcia A; Kisseberth W; Couto G J Am Anim Hosp Assoc; 2013; 49(6):370-7. PubMed ID: 24051260 [TBL] [Abstract][Full Text] [Related]
26. A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma. Teske E; Rutteman GR; Kirpenstein J; Hirschberger J Vet Comp Oncol; 2011 Dec; 9(4):283-9. PubMed ID: 22077409 [TBL] [Abstract][Full Text] [Related]
27. Prognostic value of tumour-related factors associated with canine retroperitoneal hemangiosarcoma in comparison with other anatomic presentations: A retrospective observational study. Furukawa T; Shiotsuki A; Okada Y; Nibe K; Tei M; Anazawa T; Yoshikawa M; Ono K; Hirao H Vet Med Sci; 2024 Jul; 10(4):e1495. PubMed ID: 38889089 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of doxorubicin-based chemotherapy for non-resectable canine subcutaneous haemangiosarcoma. Wiley JL; Rook KA; Clifford CA; Gregor TP; Sorenmo KU Vet Comp Oncol; 2010 Sep; 8(3):221-33. PubMed ID: 20691029 [TBL] [Abstract][Full Text] [Related]
29. Pilot safety evaluation of doxorubicin chemotherapy combined with non-specific immunotherapy (Immunocidin®) for canine splenic hemangiosarcoma. Musser ML; Coto GM; Lingnan Y; Mochel JP; Johannes CM PLoS One; 2022; 17(12):e0279594. PubMed ID: 36548371 [TBL] [Abstract][Full Text] [Related]
30. Timely adjuvant chemotherapy improves outcome in dogs with non-metastatic splenic hemangiosarcoma undergoing splenectomy. Faroni E; Sabattini S; Guerra D; Iannuzzi C; Chalfon C; Agnoli C; Stefanello D; Polton G; Ramos S; Aralla M; Ciaccini R; Foglia A; Okonji S; Marconato L Vet Comp Oncol; 2023 Mar; 21(1):123-130. PubMed ID: 36633399 [TBL] [Abstract][Full Text] [Related]
31. Vincristine sulfate as single-agent chemotherapy in a dog and a cat with malignant neoplasms. Hahn KA J Am Vet Med Assoc; 1990 Aug; 197(4):504-6. PubMed ID: 2211297 [TBL] [Abstract][Full Text] [Related]
32. Effects of indinavir in a preliminary phase I study on dogs with stage III slenic hemangiosarcoma. Spugnini EP; Esposito V; Groeger AM; Cassandro R; Onori N; Chirianni A; Baldi A In Vivo; 2006; 20(1):125-7. PubMed ID: 16433040 [TBL] [Abstract][Full Text] [Related]
33. Treatment with DAV for advanced-stage hemangiosarcoma in dogs. Dervisis NG; Dominguez PA; Newman RG; Cadile CD; Kitchell BE J Am Anim Hosp Assoc; 2011; 47(3):170-8. PubMed ID: 21498593 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of clinical and histologic factors associated with survival time in dogs with stage II splenic hemangiosarcoma treated by splenectomy and adjuvant chemotherapy: 30 cases (2011-2014). Moore AS; Rassnick KM; Frimberger AE J Am Vet Med Assoc; 2017 Sep; 251(5):559-565. PubMed ID: 28828962 [TBL] [Abstract][Full Text] [Related]
36. Anticancer effects of resveratrol in canine hemangiosarcoma cell lines. Carlson A; Alderete KS; Grant MKO; Seelig DM; Sharkey LC; Zordoky BNM Vet Comp Oncol; 2018 Jun; 16(2):253-261. PubMed ID: 29235249 [TBL] [Abstract][Full Text] [Related]
37. In vitro effects of doxorubicin and tetrathiomolybdate on canine hemangiosarcoma cells. Sloan CQ; Rodriguez CO Am J Vet Res; 2018 Feb; 79(2):219-225. PubMed ID: 29359968 [TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical detection of a potential molecular therapeutic target for canine hemangiosarcoma. Adachi M; Hoshino Y; Izumi Y; Takagi S J Vet Med Sci; 2016 May; 78(4):649-56. PubMed ID: 26685984 [TBL] [Abstract][Full Text] [Related]
39. [Adjuvant treatment of canine splenic hemangiosarcoma with autologous dendritic cell therapy - a prospective, randomized double-blind study]. Reck A; Gedon J; Kessler M Tierarztl Prax Ausg K Kleintiere Heimtiere; 2023 Dec; 51(6):394-402. PubMed ID: 38056478 [TBL] [Abstract][Full Text] [Related]
40. [Hemangiosarcoma of the spleen: clinical aspects in 52 dogs]. Kessler M; Maurus Y; Köstlin R Tierarztl Prax Ausg K Kleintiere Heimtiere; 1997 Nov; 25(6):651-6. PubMed ID: 9459832 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]